Tafenoquine Succinate

• CAT Number: R039939
• CAS Number: 106635-81-8
• Molecular Formula: C28H34F3N3O7
• Molecular Weight: 581.58
• Purity: ≥95%
• Storage: 2-8°C
• IUPAC Name: butanedioic acid;4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
• InChI: InChI=1S/C24H28F3N3O3.C4H6O4/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27;5-3(6)1-2-4(7)8/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3;1-2H2,(H,5,6)(H,7,8)
• InChIKey: CQBKFGJRAOXYIP-UHFFFAOYSA-N
• SMILES: CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC.C(CC(=O)O)C(=O)O

Tafenoquine Succinate (Cat No.:R039939) is an 8-aminoquinoline compound primarily used as an antimalarial prophylaxis. It is effective against Plasmodium vivax and Plasmodium falciparum malaria parasites. Tafenoquine is unique in its long half-life, allowing for a single-dose regimen for both prophylaxis and radical cure of P. vivax malaria. It works by targeting the dormant liver-stage parasites (hypnozoites) responsible for relapses in P. vivax malaria. Tafenoquine has shown efficacy in preventing malaria infection and reducing the risk of relapse, providing an important tool in the fight against malaria.